New CEO and acquisitions at inVentiv

Share this article:
InVentiv Health announced a pair of big acquisitions as a leading private equity investor took the helm of the holding company.
InVentiv named executive chairman Paul Meister to replace Blane Walter as CEO while Walter stepped back, taking the title vice chairman.
The company also announced its acquisitions of management consulting firm Campbell Alliance and contract research organization i3. InVentiv paid around $400 million for the i3 business. Terms of the much smaller Campbell Alliance deal were not disclosed.
Meister is founder and CEO of Liberty Lane Partners, LLC, which is part of the investment group that acquired inVentiv in August. He served in executive roles at Fisher Scientific from 1991 to 2006, including chairman of the board for Thermo Fisher Scientific Inc. and vice chairman of Fisher Scientific International.
Walter founded advertising and marketing services conglomerate inChord, which merged with contract sales firm Ventiv in 2005.  
“Blane's vision has led inVentiv to become one of the top service providers in the healthcare industry,” said Meister in a statement. “We are now well-positioned to grow our leadership position and are very pleased that Blane will continue to provide strategic counsel as vice chairman of our board.”
With the Campbell Alliance and i3 acquisitions, the company is reorganizing into three self-standing divisions—clinical, consulting and commercial. The clinical segment will include i3 and inVentiv's inVentiv Clinical Solutions, MedFocus and Smith Hanley. Consulting will consist of Campbell Alliance, which will incorporate inVentiv's Advance Insights business. Commercial will house inVentiv Health's communications, selling solutions, selling accelerators and patient outcomes businesses, all operating under the inVentiv Health umbrella. That division, the holding company's largest, is worth around $900 million in annual revenue.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?